Altre lingue Venus Medtech (Hangzhou) Inc.

Azioni

2500

CNE100003PJ8

Mercato chiuso - Hong Kong S.E. Altri mercati azionari 09:08:30 22/11/2023			Variaz. 5gg	Var. 1 gen.
5,62 ^HKD	-0,71%		-.--%	-.--%

01/04	Venus Medtech riduce la perdita nel 2023, mentre il fatturato cresce di quasi il 21%.	MT
28/03	Venus Medtech (Hangzhou) Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Venus Medtech Trims Loss in 2023 as Revenue Grows Nearly 21%	01/04
Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Venus Medtech Inc.(SEHK:2500) dropped from S&P Global BMI Index	18/03
Venus Medtech Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away	07/02
Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval	05/02
Venus Medtech Names Former 3SBio Finance Chief as CFO	04/01
Venus Medtech Inc. Appoints Fei Wang as the Chief Financial Officer	04/01
Venus Medtech Gets Trading Resumption Guidance	27/12
Venus Medtech Inc. Approves Mr. Liqiao Ma as an Executive Director	15/12
Venus Medtech Concludes Probe into Funds Loaned to Ex-Directors; Declares Remedial Action	28/11
Venus Medtech to Market Valgen Medtech's Heart Valve Repair System Across China	22/11
Venus Medtech Inc. Announces Executive Changes	20/11
Venus Medtech's Exciting Innovations for Structural Heart to Be Showcased at London Valves 2023	19/11
Venus Medtech Names Joint CEO	25/09/23
Venus Medtech Inc. Announces Appointment of Mr. Lim Housen (Lin Haosheng) as Joint Chief Executive Officer with Effect from September 22, 2023	22/09/23
Venus Medtech's H1 Attributable Loss Widens	01/09/23
Venus Medtech Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	31/08/23
US FDA Grants Clinical Trial Approval to Venus Medtech's Pulmonary Valve Replacement	07/08/23
Venus Medtech Inc. Announces it's Self-Developed Transcatheter Pulmonary Valve Replacement System VenusP-Valve Received the Approval of IDE (Investigational Device Exemption) Application from the US Food and Drug Administration	06/08/23
Venus Medtech’s General Manager Boosts Shareholding to 12%	13/06/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Venus Medtech (Hangzhou) Inc.

Azioni

2500

CNE100003PJ8

Altre lingue

Filtri